Effecto del drenaje en los vertisuelos sobre la salinidad y el rendimiento del sorgo de grano

International audienc

Urolitiasis de estruvita en perros: Características epidemiológicas y clínicas en México

Objective. Identify demographic risk factors and clinical characteristics of struvite urolithiasis (UEs) in a canine population from Mexico. Animals. Dog cases with struvite urolith from the urolith analysis laboratory from 2012-2017. Materials and methods. A comparative cross-sectional study was conducted to identify demographic risk factors in dogs with UEs by comparing cases between two groups. Description of the clinical characteristics, they will be used in clinical data of dogs with UEs. Statistical analysis included X2 test, odds ratio (OR) and confidence interval (95% CI). Significant values were considered with p<0.05. Multivariate logistic regression analysis was used to identify association between factors. Results. The UEs frequency was 41.2% and female dogs were greater odds at for developing this urolithiasis (p<0.05; p <0.001) across all comparison groups, as well as the small-size animals (p<0.01) with respect to large-sized ones. Associations between a struvite urolithiasis diagnosis and individual breeds and age were identified. The clinical characteristics found were urine pH ≥7, specific gravity ≥1.025, presence of moderately radiopacity uroliths ≥30 mm and solitary into the bladder in female. Recurrence was more frequently between the first and second year (56.7%). Conclusions. The identification of these demographic factors and the knowledge of clinical characteristics will allow veterinarians to predict that the urolith composition is struvite and consider medical dissolution as treatment.Objetivo. Identificar factores de riesgo demográficos y características clínicas de la urolitiasis de estruvita en perros de México. Animales. Casos clínicos de perros con urolitiasis de estruvita obtenidos de la base de datos del laboratorio de análisis de urolitos del 2012-2017. Materiales y Métodos. Se realizó un estudio transversal comparativo para identificar factores de riesgo demográficos mediante la comparación de casos entre dos grupos. En la descripción de las características clínicas se utilizaron datos clínicos de los casos. El análisis estadístico incluyó prueba de X2, razón de probabilidades (OR) e intervalo de confianza del 95%, considerando como valor significativo una p<0.05. El análisis de regresión logística multivariada se utilizó para identificar asociación entre factores. Resultados. La frecuencia de la urolitiasis de estruvita fue del 41.2%. Las hembras tuvieron mayor probabilidad de desarrollar esta urolitiasis (p<0.05; p<0.001) en todos los grupos de comparación, asi como los animales de talla pequeña (p<0.01) con respecto a los de talla grande. Asociaciones entre un diagnóstico de urolitiasis de estruvita y las razas individuales y edad fueron identificadas. Las características clínicas encontradas fueron pH urinario ≥7, densidad urinaria ≥1.025, presencia de urolitos moderadamente radiopacos ≥30 mm y únicos en vejiga de las hembras. La recurrencia fue más frecuente entre el primer y segundo año (56.7%). Conclusiones. La identificación de los factores demográficos y de las características clínicas ayudará a los clínicos veterinarios a predecir la composición mineral del urolito de estruvita, y así poder considerar la disolución médica como tratamiento

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 \+/-\ bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) \+/-\ bev in patients (pts) with metastatic colorectal cancer (mCRC)

International audience3502 Background: The SIRFLOX study was designed to assess the efficacy and safety of combining FOLFOX chemotherapy (\+/-\ bev) with SIRT using yttrium-90 (Y-90) resin microspheres as first-line treatment of pts with liver metastases from mCRC. Methods: SIRFLOX was an international, multi-center, open-label, RCT in chemotherapy-naive pts with non-resectable, liver only or liver dominant (liver plus lung and/or lymph node metastases) mCRC. Arm A: mFOLFOX6 \+/-\ bev was compared to arm B: mFOLFOX6 + SIRT (SIR-Spheres; Sirtex) administered once with cycle 1 \+/-\ bev until disease progression. The primary endpoint was progression free survival (PFS) using RECIST v1.0. Stratification variables included presence of extra hepatic disease (EHD; liver only v liver dominant), degree of liver involvement ( [≤] 25% v \textgreater 25%), and treatment with bev (at clinician discretion). Results: From Oct 2006 to Apr 2013,530 pts were randomised (arm A, n = 263; arm B, n = 267), 212 (40%) had EHD. Median follow-up was 36.1 months. The median overall PFS was 10.2 v 10.7 months in arms A v B respectively (hazard ratio [HR]: 0.93; 95% CI 0.77-1.12; p=0.428) by Kaplan Meier analysis. The median PFS in the liver was 12.6 v 20.5 months in arm A v B (HR: 0.69; 95% CI 0.55-0.90; p = 0.002) by competing risk analysis. Overall response rate (PR + CR) was 68.0% v 76.4% in arm A v B, respectively (p = 0.113). Hepatic response rate was 68.8% v 78.7% in arm A v B (p = 0.042), including CR rate 1.9% v 6.0% (p = 0.02). The liver resection rate was 13.7% v 14.2% in arm A v B (p = 0.857). Adverse events [≥] grade 3 were noted in 73.3% v 85.4% of pts in arm A v B. Most common toxicities were hematologic; 32.9% v 51.2% and gastrointestinal; 21.2% v 32.9%, including gastric ulcer 0.0% v2.4%. Conclusion: In first-line treatment of pts with non-resectable CRC liver metastases, the addition of SIRT to standard chemotherapy failed to improve overall PFS. However, median liver PFS was significantly extended. The addition of SIRT was associated with acceptable toxicity. Overall survival analyses, combining data from SIRFLOX and two other ongoing studies in this disease setting, are awaited. Clinical trial information: NCT0072450

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

International audiencePURPOSE: SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer. PATIENTS AND METHODS: Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab. The primary end point was progression-free survival (PFS) at any site as assessed by independent centralized radiology review blinded to study arm. RESULTS: Between October 2006 and April 2013, 530 patients were randomly assigned to treatment (control, 263; SIRT, 267). Median PFS at any site was 10.2 v 10.7 months in control versus SIRT (hazard ratio, 0.93; 95% CI, 0.77 to 1.12; P = .43). Median PFS in the liver by competing risk analysis was 12.6 v 20.5 months in control versus SIRT (hazard ratio, 0.69; 95% CI, 0.55 to 0.90; P = .002). Objective response rates (ORRs) at any site were similar (68.1% v 76.4% in control v SIRT; P = .113). ORR in the liver was improved with the addition of SIRT (68.8% v 78.7% in control v SIRT; P = .042). Grade ≥ 3 adverse events, including recognized SIRT-related effects, were reported in 73.4% and 85.4% of patients in control versus SIRT. CONCLUSION: The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant or liver-only metastatic colorectal cancer did not improve PFS at any site but significantly delayed disease progression in the liver. The safety profile was as expected and was consistent with previous studie